This participation aligns with our commitment to engage with industry leaders and investors. Our presentation will offer insight into our company's growth strategy and market position.
John Lai, Chief Executive Officer for PetVivo, commented, "We are pleased to be invited and to present at Spartan Capital's inaugural investor conference. This event provides an excellent platform to showcase our company and keep the key influencers in the capital markets apprised of our accomplishments and future plans."
Mr. Lai intends to provide an overview of PetVivo Holdings, Inc. as well as discuss its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
The conference, organized in partnership with B2i Digital, a leading digital marketing firm specializing in investor communications, will feature presentations from over 30 carefully selected companies. The event will include panel discussions, one-on-one meetings, and networking sessions to maximize interactions between investors and presenters.
“We’re privileged to welcome PetVivo Holdings, Inc. to this pivotal event and showcase their accomplishment on b2idigital.com and with our 950K+ sophisticated investor community across social media,” added David Shapiro, CEO of B2i Digital.
John D. Lowry, Founder and Chief Executive Officer of Spartan Capital Securities, LLC, stated, "Our inaugural investor conference commemorates Spartan Capital's 17 years as a trusted leader in the capital markets. It underscores our commitment to building meaningful connections between client companies and our sophisticated investor base.
The Pierre is an ideal venue for our clients to explore capital formation opportunities and strengthen relationships."
For more information about the conference and registration details, please visit Spartan Capital's conference page.
For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
To learn more about PetVivo as a publicly traded company, contact John Lai of PetVivo at (952) 405-6216 or please email us at info1@petvivo.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company's story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant investors to each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com.
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
212.579.4844 Office
https://www.linkedin.com/in/davidshapironyc
https://www.linkedin.com/company/b2i-digital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://www.pinterest.com/b2idigital
https://www.tiktok.com/@b2idigital
https://stocktwits.com/B2iDigital
https://www.reddit.com/r/b2i_digital
https://www.threads.net/@b2i_digital
About Spartan Capital Securities, LLC
Spartan Capital Securities, LLC, is a premier full-service financial firm offering expert investment advice to high-net-worth individuals and institutional clients. Known for its extensive market knowledge, strategic risk management, and personalized service, Spartan Capital and CEO John Lowry exemplify integrity and professionalism in the financial services industry.
Spartan Capital Securities Contact:
Kim Monchik
45 Broadway, 19th Floor
New York, NY 10006
212.293.0123
https://www.linkedin.com/company/spartan-capital-securities-llc/
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.